Fulgent Genetics Inc (OQ:FLGT)
Business Focus: Medical & Diagnostic Laboratories
| Sector: Healthcare | Industry: Healthcare Facilities & Services |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 4978 Santa Anita Ave Ste 205 TEMPLE CITY CA 91780-3600 |
| Tel: | 1-415-2172633 |
| Website: | https://www.fulgentgenetics.com |
| IR: | See website |
| Key People | ||
| Ming Hsieh Chairman of the Board, President, Chief Executive Officer | Paul Kim Chief Financial Officer | Jian Xie Chief Operating Officer | Han Lin Gao Chief Scientific Officer, Laboratory Director |
| Business Overview |
| Fulgent Genetics, Inc. is a technology company, which offers COVID-19 testing services, molecular diagnostic testing services and comprehensive genetic testing designed to provide physicians and patients with clinically actionable diagnostic information to improve the patient care quality. The Company develops a technology platform, which offers a test menu. It performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. It also offers certain research service tests, which are ordered by research institutions and other similar institutional customers. |
| Financial Overview |
| For the nine months ended 30 September 2022, Fulgent Genetics Inc revenues decreased 26% to $551.3M. Net income decreased 59% to $167.2M. Revenues reflect Insurance segment decrease of 41% to $236.3M, Institutional segment decrease of 7% to $314.2M. Net income also reflects General and administrative increase from $26.3M to $76.1M (expense), Selling and marketing increase of 76% to $25.5M (expense). |
| Employees: | 645 as of Feb 1, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $453.29M as of Sep 30, 2022 |
| Annual revenue (TTM): | $802.94M as of Sep 30, 2022 |
| EBITDA (TTM): | $395.32M as of Sep 30, 2022 |
| Net annual income (TTM): | $271.57M as of Sep 30, 2022 |
| Free cash flow (TTM): | $277.33M as of Sep 30, 2022 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 29,438,052 as of Nov 1, 2022 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2023 INK Research Corp. All rights reserved.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.